ZLAB

Investor Moves

Name	Value	Action	Change	Price	Last Price
Ron BaronBaron Capital $31M1.7M shares AddQ1 2026 $6M $18.81 $20.75
Ken GriffinCitadel Advisors $32M1.7M shares AddQ1 2026 $2M $18.81 $20.75

Insider Trades

Name	Value	Action	Price	Last Price
Du YingDirector, Officer: Chairperson & CEO $1M50k shares SellMay 15, 2026 $20.74 $20.75
Du YingDirector, Officer: Chairperson & CEO $950k50k shares SellMay 18, 2026 $19.00 $20.75
Du YingDirector, Officer: Chairperson & CEO $1M50k shares SellMay 14, 2026 $20.09 $20.75
Du YingDirector, Officer: Chairperson & CEO $683k33.8k shares SellMay 13, 2026 $20.22 $20.75
Du YingDirector, Officer: Chairperson & CEO $316k16.2k shares SellMay 13, 2026 $19.44 $20.75
Edmondson Frazor Titus IIIChief Legal Officer $71k3.5k shares SellMay 14, 2026 $20.19 $20.75

News

businesswire.comZai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomasbusinesswire.comJun 16

businesswire.comZai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancerbusinesswire.comJun 8

businesswire.comZai Lab Announces Changes to Senior Leadership Teambusinesswire.comMay 21

seekingalpha.comZai Lab: A Speculative Bet On Global Oncology, With A Greater China Bag Attachedseekingalpha.comMay 13

businesswire.comZai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)businesswire.comMay 11

Trade ZLAB

About Zai Lab Limited

Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders. Currently available products in their portfolio include Zejula, a once-daily small-molecule PARP 1/2 inhibitor; Optune, a medical device leveraging tumor treating fields; NUZYRA, an antimicrobial agent for specific acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors. Beyond its commercial offerings, Zai Lab boasts an extensive pipeline of investigational therapies. These include Odronextamab for various B-cell lymphomas; Repotrectinib, a tyrosine kinase inhibitor targeting ROS1 and TRK pathways in both TKI-naïve and pretreated cancer patients; Margetuximab for breast and gastroesophageal cancers; Adagrasib for KRAS-G12C-mutated solid tumors like NSCLC, colorectal, and pancreatic cancers; and Bemarituzumab for gastric and gastroesophageal junction cancers. Further pipeline candidates encompass CLN-081 for EGFR exon 20 insertion NSCLC; Elzovantinib, an orally available multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab, designed to block PD-1 interactions with its ligands; ZL-2309, an orally active and selective CDC7 kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod, aimed at reducing pathogenic immunoglobulin G antibodies; ZL-1102, a human nanobody against interleukin-17A; KarXT for psychiatric and neurological conditions; ZL-2313 and ZL-2314, both investigational EGFR inhibitors targeting specific mutations; and Sulbactam/durlobactam, intended for serious infections caused by Acinetobacter. Established in 2013, Zai Lab Limited maintains its corporate headquarters in Shanghai, China.

CEO: Ying Du
IPO Date: Sep 20, 2017

Market Data

Open: $18.52
High: $18.96
Low: $18.15
Volume: 959.3K
Avg Volume: 866.7K
52W High: $41.20
52W Low: $15.96

Valuation

Market Cap: $2B
Enterprise Value: $1.5B
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$158.9M
Revenue: $460.2M
Net Income: -$175.5M
Cash: $679.6M
Debt: $224.3M

Events

EarningsAug 6

EPS est. -0.66764